PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone

• Status: Completed
• Trial end date: 1969-12-31

Summary

• To evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer

• To evaluate PSA (tumor marker) response rate

• To evaluate safety

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Docetaxel; Hormones; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate